U.S. Court in Texas Backs FDA’s Removal of Lilly’s Weight Loss Medication from Drug Shortage List
- May 09, 2025
Drug compounders lost their challenge this week to the Food and Drug Administration’s (FDA’s) decision to remove tirzepatide, the active ingredient in Eli Lilly & Co.’s weight loss and diabetes medications Zepbound and Mounjaro, from the agency’s drug shortage list.
ARTICLE TAGS
You must be logged in to access this content.